Zacks Research Has Weak Estimate for Danaher FY2024 Earnings

Danaher Co. (NYSE:DHR) – Stock analysts at Zacks Research dropped their FY2024 earnings estimates for shares of Danaher in a research report issued on Tuesday, November 12th. Zacks Research analyst R. Department now anticipates that the conglomerate will earn $7.49 per share for the year, down from their previous forecast of $7.56. The consensus estimate for Danaher’s current full-year earnings is $7.51 per share. Zacks Research also issued estimates for Danaher’s Q4 2024 earnings at $2.14 EPS, Q1 2025 earnings at $2.05 EPS, Q2 2025 earnings at $1.91 EPS, Q3 2025 earnings at $1.94 EPS, Q4 2025 earnings at $2.34 EPS, FY2025 earnings at $8.24 EPS, Q1 2026 earnings at $2.21 EPS, Q2 2026 earnings at $2.25 EPS and FY2026 earnings at $9.28 EPS.

Several other brokerages have also commented on DHR. Wolfe Research upgraded Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price target on the stock in a research note on Thursday, October 31st. UBS Group cut their price target on Danaher from $309.00 to $305.00 and set a “buy” rating on the stock in a research note on Wednesday, October 23rd. Stephens restated an “overweight” rating and set a $315.00 price target on shares of Danaher in a research note on Wednesday, October 23rd. Barclays cut their price target on Danaher from $285.00 to $275.00 and set an “equal weight” rating on the stock in a research note on Wednesday, October 23rd. Finally, Stifel Nicolaus raised their price target on Danaher from $250.00 to $265.00 and gave the company a “hold” rating in a research note on Wednesday, October 23rd. Five analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to data from MarketBeat, Danaher currently has a consensus rating of “Moderate Buy” and an average price target of $287.16.

Danaher Stock Performance

DHR stock opened at $230.51 on Thursday. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 0.32. The business’s fifty day simple moving average is $262.91 and its two-hundred day simple moving average is $260.49. Danaher has a twelve month low of $206.30 and a twelve month high of $281.70. The firm has a market cap of $166.49 billion, a price-to-earnings ratio of 45.00, a PEG ratio of 4.44 and a beta of 0.85.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, topping the consensus estimate of $1.57 by $0.14. The business had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The firm’s revenue for the quarter was up 3.1% compared to the same quarter last year. During the same period in the prior year, the company posted $2.02 EPS.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Prestige Wealth Management Group LLC raised its position in Danaher by 22.0% during the third quarter. Prestige Wealth Management Group LLC now owns 1,528 shares of the conglomerate’s stock valued at $425,000 after acquiring an additional 276 shares in the last quarter. Adalta Capital Management LLC increased its position in shares of Danaher by 52.3% in the third quarter. Adalta Capital Management LLC now owns 8,467 shares of the conglomerate’s stock valued at $2,356,000 after buying an additional 2,907 shares in the last quarter. LRI Investments LLC increased its position in shares of Danaher by 82.5% in the third quarter. LRI Investments LLC now owns 4,545 shares of the conglomerate’s stock valued at $1,264,000 after buying an additional 2,055 shares in the last quarter. Gordian Capital Singapore Pte Ltd increased its position in shares of Danaher by 26.1% in the third quarter. Gordian Capital Singapore Pte Ltd now owns 1,400 shares of the conglomerate’s stock valued at $389,000 after buying an additional 290 shares in the last quarter. Finally, PYA Waltman Capital LLC increased its position in shares of Danaher by 3.0% in the third quarter. PYA Waltman Capital LLC now owns 33,368 shares of the conglomerate’s stock valued at $9,277,000 after buying an additional 970 shares in the last quarter. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, SVP Georgeann Couchara sold 952 shares of Danaher stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the transaction, the senior vice president now directly owns 4,212 shares in the company, valued at approximately $1,130,374.44. This trade represents a 18.44 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 11.10% of the company’s stock.

Danaher Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, October 25th. Investors of record on Friday, September 27th were issued a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.47%. The ex-dividend date of this dividend was Friday, September 27th. Danaher’s dividend payout ratio (DPR) is 20.61%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.